Bimeda Inc. is pleased to announce the formal renaming of acquired vaccine production, research and diagnostic company, Texas Vet Lab, Inc., as Bimeda Biologicals Inc. Both Texas Vet Lab, Inc. (TVL) and the VetBio, Inc. divisions of the business will henceforth operate under the new legal name of Bimeda Biologicals Inc.

Dave Cunningham, Bimeda's Chief Commercial Officer, commented, 'the renaming of the organization represents the first phase of our branding strategy and the continued integration of the TVL business, which is designed to see the company reach its potential both in domestic and export markets. The new name, Bimeda Biologicals Inc, respects the core identity of the business, while formally incorporating it into the Bimeda group of companies.'

Bimeda acquired the Texas-based biologicals business in December 2019, marking an important step for the company into the area of preventative medicines. At the time, Bimeda noted the company's significant potential for sustainable long-term growth and made a commitment to substantial investments to drive growth for both the existing vaccine portfolio and new product offerings.

For press queries, contact:
Dave Cunningham, Bimeda Chief Commercial Officer

Email: 

Bimeda^® is pleased to announce Rey Armendariz in the new role of Regional Strategic Manager. Effective immediately, Rey will be an integral part of the food animal sales team and assist in the sales development in feedlots for both core Bimeda products and the newly acquired bovine biologicals commercial and custom vaccine lines. Rey will assist the food animal business unit by also facilitating the business development and creation of strategies for key strategic feedlot accounts throughout a three-state territory (Kansas, Nebraska and Colorado).

Rey has 21 years of experience in multiple segments of the animal health industry working for Fort Dodge Animal Health and most recently with Zoetis in the confined feeding area.

Bimeda is very proud to add Rey to our growing food animal business unit.

Bimeda is pleased to announce the acquisition of Texas Vet Lab, Inc (TVL). Established in 1977 and located in San Angelo, Texas, TVL specialises in bovine vaccine research and production, with a broad range of live and inactivated vaccines to protect against cattle respiratory diseases.

Company CEO Gavin Tierney, commented; 'the acquisition of Texas Vet Lab marks an important step for Bimeda into the arena of preventative medicine. Following on from the integration of TVL, Bimeda is able to offer our customers a broad suite of both preventative and curative treatment options, including vaccines, antimicrobials, anti-parasitics, hormones, and anti-inflammatories.'

Tierney added, 'TVL also boasts an on-site laboratory, which provides diagnostics for antibiotic sensitivity, as well as virus and bacteria isolation and identification. This will allow us to provide customers with a diagnostics-led approach to the treatment of their animals; ensuring maximum efficacy and rapid recovery from disease.'

The US cattle vaccine market has demonstrated strong annual growth over the past five years and this trend is set to continue in line with the global movement towards preventative medicine, and a more targeted use of antibiotics. Against this backdrop, the acquisition will serve as an important tool for Bimeda's long-term growth strategy in the US.

Dave Cunningham, Bimeda's Chief Commercial Officer for North America, commented; 'Texas Vet Lab is an exciting acquisition for Bimeda. With decades of experience in developing innovative vaccines, the TVL team brings a commitment to quality, innovation and serving the customer which perfectly aligns with Bimeda's own values. We see significant long-term growth potential for the business, and with our substantial planned investments in R&D, Sales and Marketing, we will drive growth for both the existing vaccine portfolio and new product offerings.'

Director of Research & Development
Director of Research & Development, Bimeda Biologicals

National Account Manager - Cattle
USA

Senior Territory Manager
Colorado & West Kansas

Senior Territory Manager
Eastern New Mexico, Texas Panhandle, Oklahoma

Not All Adjuvants are Created Equal

Bimeda^® Biologicals Inc. was formed following Bimeda’s acquisition of Texas Vet Lab^®, Inc. (as well as their wholly owned subsidiaries VetBio^™, Inc. and Allied Biologics Company^™ Inc.) which have been in business since 1977. Our new name respects the core identity of the business, while formally incorporating it into the Bimeda group of companies.

Our state-of-the-art production facility, as well as our diagnostic and research labs, are located in San Angelo, Texas a city in the western part of the state that sits on the Concho River.

Staying true to the core competencies of Texas Vet Lab (TVL), we are a vaccine production, research and diagnostics company. We specialize in bovine biologicals and focus on the development of effective vaccines that provide immunity against existing and emerging diseases that affect stocker/feeder cattle.

In 2021 we have invested in both facilities and expertise to enter into the swine autogenous market segment by expanding our production facilities in San Angelo and opening a swine-focused state-of-the-art research and development lab in St. Paul, Minnesota. With our new R&D lab and expanded production facilities, our experienced swine team is able to provide veterinarians and producers support with strain selection, database management, whole genome sequencing (WGS), metagenomics, bioinformatics, clinical trials all in an effort to produce effective autogenous vaccines to improve their animals’ health and productivity.

Our talented team, which includes the legacy leadership and majority of TVL staff, strives to equip veterinarians and livestock producers with the tools and information they need to keep the animals in their care healthy and productive so that they can be profitable.

With the addition of the biological products and diagnostic services, Bimeda US is now able to provide livestock producers and veterinarians preventative solutions in addition to their existing portfolio which focused on five key categories including ecto- and endo-parasiticides, water soluble antimicrobials, injectables and nutritional products visit Bimeda USA to learn more.

To support veterinarians and livestock producers in their efforts toward keeping the animals they care for healthy and productive by providing them relevant, science-based solutions--through our vaccine production, research and diagnostic services—to effectively address the challenges they face.

Texas Vet Lab, Inc. was established in 1977 by Dr. W.H. (Bill) Wohler. Working alongside his wife Patsy, the company committed its future to the development of more effective vaccines against shipping fever pneumonia and bovine respiratory disease. While Texas Vet Lab was starting as a new company, Dr. Wohler also owned and managed cattle through all segments and phases of the beef industry. Working as a veterinary consultant and vested feeding partner with many of his customers and friends, Dr. Wohler’s affinity, understanding, and practical application of veterinary microbiology led to the creation of several novel vaccines and the facility received full licensure by the USDA in 1981.

Over the course of the 40-year period following their establishment, Texas Vet Lab evolved into a complete vaccine production, research and diagnostic company. They primarily focused on the development of commercial and autogenous bovine biologicals to provide immunity against existing and emerging diseases that affect stocker and feeder cattle.

The first commercial vaccine they developed was their Poly-Bac^® vaccine that targeted pneumonia/shipping fever. It  was the first killed vaccine containing Mannheimia (Pasteurella) haemolytica to be proven effective by the modern test methods in young feeder cattle.

In 1999, Texas Vet Lab became the first and only company to provide “Dual Coverage” for Mannheimia haemolytica with the addition of the more virulent Type A6 into their Poly-Bac vaccines along with the more common Type A1 that was present in other bacterial vaccines. This unique feature of the vaccine line is still true today!

Another novel development was the first USDA approval of a fully licensed Mycoplasma bovis vaccine that was originally named Myco-Bac^® B. Most often referred to as “Myco”, this disease is one of the most prevalent and isolated diseases in cattle today and is an especially difficult bug to treat.

With the untimely passing of Dr. Wohler in 2007, the business transitioned to the general management and ownership of Jim Bob Harris. Mr. Harris has a B.S. in Animal Science from Angelo State University and gained a M.S. degree in Veterinary Microbiology from Texas A&M University in 1989. In 2013, virologist Dale Weise, a 20+ year veteran at TVL, also purchased ownership in the company. Mr. Weise graduated from Texas A&M University with a B.S. in Biomedical Science and a M.S. degree in Veterinary Pharmacology.

Under the direction of their new leadership, Texas Vet Lab was able to expand their Poly-Bac line of vaccines and provide a number of unique combinations targeting the most common BRD-causing bacteria. In 2012, they gained approval for their Stimulator^® line of modified-live virus vaccines which were developed using the most relevant strains of virus to maximize cross-protection against prevalent field strains affecting stocker and feeder cattle.

In addition to their commercially licensed and autogenous cattle vaccines and diagnostics, Texas Vet Lab has produced two vaccines to help goat and sheep producers address needs affecting their animals. This includes a conditionally licensed Corynebacterium Pseudotuberculosis bacterin labeled for goats which is a bacterial organism that causes the disease commonly referred to as Caseous Lymphadenitis or “CL”, as well as a live virus Ovine Ecthyma vaccine they produce in concert with Texas A&M AgriLife Extension Services to address sore mouth in sheep.

Through their vaccine production, research and diagnostic services Texas Vet Lab grew a loyal customer base comprised of veterinary consultants and livestock producers from across the nation.

In 2019 Texas Vet Lab, Inc. (as well as their wholly owned subsidiaries VetBio, Inc. and  Allied Biologics Company Inc.) was acquired by Bimeda Inc. and was renamed to Bimeda Biologicals Inc. The new name respects the core identity of the business, while formally incorporating it into the Bimeda group of companies. At the time, Bimeda made a commitment to substantial investments to drive growth of both the exisiting vaccine portfolio and new product offerings.

With the legacy leadership of Texas Vet Lab staying on board following the acquisition—along with the majority of their talented staff—Bimeda Biologicals will continue to build upon their vaccine production, research and diagnostic expertise to provide veterinarians and livestock producers across the nation valuable solutions and information to help them keep the animals they care for healthy and productive.